This page shows the latest Merck and Co. news and features for those working in and with pharma, biotech and healthcare.
AML is a rapidly progressing cancer of the blood and bone marrow and the most common form of acute leukaemia in adults. ... The EC approval comes just over a month after Astex and MSD – known as Merck &Co in the US and Canada – expanded their drug
Other drugs selected for negotiation were Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck &Co's Januvia (sitagliptin), Eli Lilly and Boehringer ... The plan is facing court
The list includes Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Novartis' Entresto (valsartan/sacubitril), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck &Co's Januvia (sitagliptin), Eli Lilly and ... However, the
The plan already faces at least seven court challenges from leading drugmakers and industry groups, including Merck &Co, Bristol Myers Squibb, Johnson &Johnson, Boehringer Ingelheim and the Pharmaceutical Research and Manufacturers ... Rare disease and
these innovations, and does so in a way that violates fundamental constitutional safeguards and undermines proper accountability,” the complaint reads. ... Leading drugmakers and industry groups, including Merck &Co, Bristol Myers Squibbs, Johnson
MSD – known as Merck &Co in the US and Canada – and Astex Pharmaceuticals have expanded their drug discovery collaboration, with the goal of identifying small-molecule candidates with activity towards a ... The candidates will then be handed off to
More from news
Approximately 44 fully matching, plus 540 partially matching documents found.
By Sandy Lindsey. It’s little over a year since the bell first rang on the New York Stock Exchange announcing the arrival of Organon &Co, a spin-off from MSD ... known as Merck &Co in the US and Canada) with a mission to create improved health outcomes
Similarly, Novartis formed the investment firm Novartis Venture Funds and Merck &Co. ... created the Merck Research Venture Fund. Nowadays, having a venture arm to proactively research for outside R&D sourcing is common for most mid- to large- sized
Bayer and Merck &Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form ... Bayer and Merck &Co hope that radiologists
like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.
Ex-Merck &Co. scientist Joshua Boger did want the company to pioneer rationale drug discovery and development, however, and after. ... a loss in almost all of its 20+ years, and has cumulative net losses of around $3bn.
More from intelligence
Approximately 0 fully matching, plus 45 partially matching documents found.
Arnhofer joins the agency with two decades of experience in the biopharma industry, having held a variety of senior positions at Merck &Co, Bayer AG and BioNTech SE. ... Storyteq marketing collaboration and creative automation platform, in addition to
Merck &Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health. ... Clyburn joined Merck &Co in 2008 and during his time with the company, he has had responsibility for various global
Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.
Schranz. Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.
Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in
More from appointments
Approximately 4 fully matching, plus 35 partially matching documents found.
Merck &Co, Sanofi and UCB have identified the competitive advantage that patient centricity brings and are leading the way in its practical implementation. ... Patient centricity is the next market access – and will take 10 years to embed”.
With a stronger market access focus, companies can create and implement stronger marketing strategies. ... With no prior blueprint on how to ‘go digital’ in their marketing, early pioneer companies such as Merck &Co.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
No results were found
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...